Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here?

Cathie Wood is resolute on RXRX despite its slump. Should investors follow her lead into this AI-driven biotech bet now?

FDA Approves Omeros' YARTEMLEA(R) -- First and Only Therapy Indicated for TA-TMA

Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...

Caris Life Sciences: Stronger Fundamentals, Same Conclusion

Caris Life Sciences, Inc. is rated a Hold with positive EBITDA & free cash flow driven by strong MI segment performance. Read ...

What Creates a Long-Term Growth Opportunity for ClearPoint Neuro (CLPT)?

Minot Light Capital Partners, an investment management company, released its Q3 2025 investment letter. A copy of the letter ...

CytomX Therapeutics: EpCAM Is Back, Now Prove It Holds (Rating Downgrade)

CytomX Therapeutics, Inc. is downgraded to Hold ahead of key CX-2051 Phase 1 expansion data in 1Q26. Learn more about CTMX ...

How 2025 Transformed Healthcare And What Medical Experts Predict For 2026

Medical leaders reflect on 2025’s breakthroughs in AI, early detection, preventive care, and wellness—and explain how these shifts will shape healthcare priorities in 2026.